AMICUS THERAPEUTICS INC's ticker is FOLD and the CUSIP is 03152W109. A total of 201 filers reported holding AMICUS THERAPEUTICS INC in Q4 2018. The put-call ratio across all filers is 0.25 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $65,935,050 | +45.0% | 5,400,086 | +23.9% | 0.02% | +33.3% |
| Q3 2022 | $45,484,366 | +48.9% | 4,356,740 | +53.1% | 0.01% | +50.0% |
| Q2 2022 | $30,554,247 | +30.9% | 2,844,902 | +15.4% | 0.01% | +60.0% |
| Q1 2022 | $23,345,046 | -28.7% | 2,465,158 | -13.1% | 0.01% | -28.6% |
| Q4 2021 | $32,759,000 | +24.2% | 2,836,238 | +2.7% | 0.01% | +16.7% |
| Q3 2021 | $26,384,000 | -29.0% | 2,762,681 | -28.4% | 0.01% | -25.0% |
| Q2 2021 | $37,177,000 | +71.9% | 3,856,502 | +76.2% | 0.01% | +60.0% |
| Q1 2021 | $21,624,000 | -65.9% | 2,188,692 | -20.3% | 0.01% | -66.7% |
| Q4 2020 | $63,431,000 | +21.1% | 2,747,126 | -26.0% | 0.02% | +7.1% |
| Q3 2020 | $52,396,000 | -16.2% | 3,710,730 | -10.5% | 0.01% | -22.2% |
| Q2 2020 | $62,548,000 | +88.2% | 4,147,749 | +15.3% | 0.02% | +50.0% |
| Q1 2020 | $33,241,000 | -0.5% | 3,597,470 | +4.9% | 0.01% | +33.3% |
| Q4 2019 | $33,392,000 | +66.3% | 3,428,337 | +37.0% | 0.01% | +50.0% |
| Q3 2019 | $20,075,000 | -21.4% | 2,503,099 | +22.4% | 0.01% | -25.0% |
| Q2 2019 | $25,525,000 | +20.2% | 2,045,287 | +30.9% | 0.01% | +14.3% |
| Q1 2019 | $21,242,000 | +50.2% | 1,561,885 | +5.8% | 0.01% | +40.0% |
| Q4 2018 | $14,147,000 | -20.8% | 1,476,707 | 0.0% | 0.01% | -16.7% |
| Q3 2018 | $17,854,000 | -22.6% | 1,476,707 | 0.0% | 0.01% | -25.0% |
| Q2 2018 | $23,066,000 | +3.9% | 1,476,707 | 0.0% | 0.01% | 0.0% |
| Q1 2018 | $22,210,000 | +23.7% | 1,476,707 | +18.3% | 0.01% | +33.3% |
| Q4 2017 | $17,958,000 | -4.6% | 1,247,933 | 0.0% | 0.01% | -14.3% |
| Q3 2017 | $18,819,000 | +198.9% | 1,247,933 | +99.6% | 0.01% | +250.0% |
| Q2 2017 | $6,297,000 | +14.3% | 625,365 | -19.1% | 0.00% | 0.0% |
| Q1 2017 | $5,510,000 | +8.8% | 772,857 | -24.1% | 0.00% | 0.0% |
| Q4 2016 | $5,064,000 | -29.7% | 1,018,862 | 0.0% | 0.00% | -33.3% |
| Q3 2016 | $7,201,000 | +55.0% | 1,018,862 | +19.7% | 0.00% | +50.0% |
| Q2 2016 | $4,647,000 | -19.1% | 851,030 | +25.1% | 0.00% | -33.3% |
| Q1 2016 | $5,746,000 | -12.9% | 680,030 | 0.0% | 0.00% | 0.0% |
| Q4 2015 | $6,596,000 | -39.5% | 680,030 | -12.7% | 0.00% | -50.0% |
| Q3 2015 | $10,895,000 | – | 778,747 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 10,524,022 | $127,972,108 | 12.11% |
| Perceptive Advisors | 27,692,917 | $336,745,870 | 11.23% |
| Redmile Group, LLC | 16,944,621 | $206,046,591 | 9.80% |
| Finepoint Capital LP | 1,489,025 | $18,106,544 | 9.02% |
| CM Management, LLC | 450,000 | $5,472,000 | 5.81% |
| Avoro Capital Advisors LLC | 27,400,000 | $333,184,000 | 5.20% |
| MPM BioImpact LLC | 716,139 | $8,708,250 | 2.32% |
| Artal Group S.A. | 4,062,567 | $49,401 | 2.12% |
| SECTORAL ASSET MANAGEMENT INC | 803,464 | $9,770,122 | 1.90% |
| GREAT POINT PARTNERS LLC | 857,000 | $10,421,120 | 1.90% |